Swiss pharmaceutical company Novartis is investing $300 million ($288 million) in biotherapeutics development, which includes a new $100 million biologics hub at its home base in Basel.
This content was published on
1 minute
swissinfo.ch/mga
Português
pt
Novartis vai gastar 300 milhões de dólares em bioterapias
A further $110 million will be spent on research and production at a Novartis site in Slovenia and $60 million in Austria, the company announcedExternal link on Monday.
Biotherapeutics is a growing class of medicaments which are extracted or synthesized from biological material, including proteins, cells and genes to treat such conditions as cancer and autoimmune diseases.
“Across the industry, biotherapeutics account for almost one-half of all recent new drug approvals and have enormous potential to address unmet need across a wide range of diseases,” said Reto Fischer, Head of Technical Research Division, Global Drug Development.
The new Swiss biologics hub will be created on the Basel St Johann campus in Basel to complement the company’s existing NIBR biologics centre.
The Basel-headquartered Novartis, one of the world’s largest pharmaceutical companies, is currently undergoing a restructuring process. In June, it announced that 8,000 jobs would be cut from its 108,000 global work force. The 1,400 Swiss jobs that will disappear represents some 10% of the staff it employs in its home market.
French cross-border workers in Switzerland fear “discriminatory” unemployment reform
This content was published on
In the French region around Geneva, cross-border workers are protesting proposals to cut unemployment benefits for those working in Switzerland.
Swan infected with bird flu in central Switzerland
This content was published on
Switzerland has reported its first bird flu case of the season. A swan found dead in central Switzerland tested positive for the H5N1 virus.
Swiss researchers identify gene variants linked to cancer progression
This content was published on
ETH Zurich researchers explored genetic mutations’ effects on cell function and their role in cancer development and treatment using CRISPR/Cas techniques.
Explosion at Swiss company Givaudan’s US plant leaves two dead
This content was published on
Swiss flavour and fragrance maker Givaudan reported that an explosion at its Kentucky plant resulted in two deaths and several injuries.
Swisscom’s Vodafone Italia takeover cleared by Italian telecoms authority
This content was published on
Swisscom is one step closer to its planned acquisition of Vodafone Italia, as the Italian communications regulator has approved the €8 billion deal.
Swiss parliamentary committee proposes foreign aid cuts and military funding boost
This content was published on
A committee of the Swiss House of Representatives has proposed increasing funds for the military and agriculture while reducing foreign aid and asylum.
Swiss Rolex Submariner watches reach nearly $50 billion in total market value
This content was published on
The total market value of all Rolex Submariner watches ever made is nearly $50 billion, based on newly released production data.
Swiss Jew wrongfully detained due to prosecutor’s ‘bias’
This content was published on
A Jewish Swiss man was detained after the prosecutor argued he might flee to Israel. The Federal Court said this implies bias due to his Jewish faith.
US reportedly scrutinises Russian accounts UBS took over from Credit Suisse
This content was published on
The US is investigating Russian clients acquired by UBS during its takeover of Credit Suisse, according to three sources familiar with the matter.
WTO plans to reappoint Okonjo-Iweala before Trump swears in
This content was published on
Some member states of the World Trade Organization may seek to reappoint Director-General Ngozi Okonjo-Iweala, according to a document released on Tuesday.
This content was published on
The recent decision by the Swiss drugmaker to shed 7% of its workforce is more than just a cost-cutting measure - it’s a turning point for Novartis.
Novartis job cuts to heavily impact management roles
This content was published on
Of the 1,400 job cuts announced by the pharma giant in Switzerland, up to half of them will involve executive-level staff.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.